| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet Oncology 16 (15), 1547-1555, 2015 | 302 | 2015 |
| Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes I Gañán-Gómez, Y Wei, DT Starczynowski, S Colla, H Yang, ... Leukemia 29 (7), 1458-1469, 2015 | 249 | 2015 |
| Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes T Badar, KP Patel, PA Thompson, C DiNardo, K Takahashi, M Cabrero, ... Leukemia research 39 (12), 1367-1374, 2015 | 67 | 2015 |
| Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response … M Cabrero, E Jabbour, F Ravandi, Z Bohannan, S Pierce, HM Kantarjian, ... Leukemia research 39 (5), 520-524, 2015 | 64 | 2015 |
| A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes G Garcia-Manero, HJ Khoury, E Jabbour, J Lancet, SL Winski, LA Cable, ... Clinical Cancer Research 21 (5), 985-994, 2015 | 54 | 2015 |
| Assessing side-chain perturbations of the protein backbone: a knowledge-based classification of residue Ramachandran space DB Dahl, Z Bohannan, Q Mo, M Vannucci, J Tsai Journal of molecular biology 378 (3), 749-758, 2008 | 45 | 2008 |
| A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, CD DiNardo, ... Leukemia 31 (2), 318-324, 2017 | 44 | 2017 |
| Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents E Jabbour, S Faderl, K Sasaki, T Kadia, N Daver, N Pemmaraju, K Patel, ... Cancer 123 (4), 629-637, 2017 | 40 | 2017 |
| Calling variants in the clinic: informed variant calling decisions based on biological, clinical, and laboratory variables ZS Bohannan, A Mitrofanova Computational and structural biotechnology journal 17, 561-569, 2019 | 30 | 2019 |
| Unraveling myelodysplastic syndromes: current knowledge and future directions AN Chamseddine, E Jabbour, HM Kantarjian, ZS Bohannan, ... Current oncology reports 18, 1-11, 2016 | 30 | 2016 |
| Analysis of class I and II histone deacetylase gene expression in human leukemia H Yang, S Maddipoti, A Quesada, Z Bohannan, M Cabrero Calvo, S Colla, ... Leukemia & lymphoma 56 (12), 3426-3433, 2015 | 29 | 2015 |
| RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype MRH Estécio, S Maddipoti, C Bueso‐Ramos, CD DiNardo, H Yang, Y Wei, ... British journal of haematology 169 (3), 344-351, 2015 | 29 | 2015 |
| Down-regulation of EZH2 expression in myelodysplastic syndromes M Cabrero, Y Wei, H Yang, I Ganan-Gomez, Z Bohannan, S Colla, ... Leukemia research 44, 1-7, 2016 | 19 | 2016 |
| Random survival forest model identifies novel biomarkers of event-free survival in high-risk pediatric acute lymphoblastic leukemia ZS Bohannan, F Coffman, A Mitrofanova Computational and structural biotechnology journal 20, 583-597, 2022 | 15 | 2022 |
| Preclinical activity of FF-10501-01, a novel inosine-5′-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia H Yang, Z Fang, Y Wei, ZS Bohannan, I Gañán-Gómez, AA Pierola, ... Leukemia Research 59, 85-92, 2017 | 9 | 2017 |
| PDE4 differential expression is a potential prognostic factor and therapeutic target in patients with myelodysplastic syndrome and chronic myelomonocytic leukemia AN Chamseddine, M Cabrero, Y Wei, I Ganan-Gomez, S Colla, ... Clinical Lymphoma Myeloma and Leukemia 16, S67-S73, 2016 | 9 | 2016 |
| First report of a phase II prospective study of combination of hyper-CVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome-positive acute … E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet. Oncology 16 (15), 1547, 2015 | 9 | 2015 |
| Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model LS Bohannan Z, Pudupakam RS, Koo J, Horwitz H, Tsang J, Polley A, Han EJ ... Vet Comp Oncol, 2020 | 8* | 2020 |
| p38 MAPK in MDS I Gañán‐Gómez, ZS Bohannan, G Garcia‐Manero Aging (Albany NY) 7 (6), 346, 2015 | 5 | 2015 |
| A bayesian phase II randomized trial of azacitidine versus Azacitidine+ Vorinostat in patients with newly diagnosed AML or high-risk MDS with poor performance status, organ … G Garcia-Manero, X Huang, M Cabrero, CD DiNardo, N Pemmaraju, ... Blood 124 (21), 3277, 2014 | 5 | 2014 |
